Clinical Scorecard: Evaluation of Short-Term Outcomes Following Degradable Stent Insertion Versus Diverting Ileostomy in Patients with Mid-to-Low Rectal Cancer: A Retrospective Cohort Analysis

At a Glance

Key Highlights

• Anastomotic leakage incidence after laparoscopic anterior resection ranges from 3% to 20%, associated with increased mortality and reoperation.
• Temporary diverting ileostomy is standard to prevent serious complications but has multiple stoma-related morbidities.
• Degradable stent offers a novel alternative aiming to reduce stoma-related complications and avoid stoma reversal surgery.

Guideline-Based Recommendations

Diagnosis

• Confirm rectal cancer diagnosis with preoperative colonoscopic biopsy.
• Stage tumors per NCCN 2023 rectal cancer guidelines.
• Perform chest and abdomen CT and rectal MRI routinely before surgery.

Management

• Perform laparoscopic low anterior resection with total mesorectal excision for eligible patients.
• Consider degradable stent placement as an alternative to diverting ileostomy to protect colorectal anastomosis.
• Use absorbable sutures for stent fixation and intestinal tube construction during surgery.

Monitoring & Follow-up

• Assess for major complications within 30 days post-surgery including anastomotic leakage, abscess, bowel perforation, severe intestinal obstruction, and bleeding.
• Monitor for minor complications such as anastomotic stricture and mild intestinal obstruction.
• Evaluate stent degradation time via imaging studies.

Risks

• Ileostomy-related complications include peristomal dermatitis, retraction, prolapse, bleeding, hernia, permanent stoma, and need for additional surgery.
• Potential stent-specific complications include intestinal obstruction and incomplete degradation.
• Major postoperative complications classified as Clavien-Dindo ≥ IIIa require close attention.

Patient & Prescribing Data

Patients with mid-to-low rectal cancer undergoing laparoscopic low anterior resection, aged 18-80 years, with no distant metastasis and suitable for anus-preserving surgery.

Degradable stent placement may reduce stoma-related morbidity and avoid the need for stoma reversal surgery compared to diverting ileostomy, with comparable short-term safety.

Clinical Best Practices

• Ensure strict inclusion and exclusion criteria to select appropriate candidates for degradable stent or ileostomy.
• Use computer-generated randomization and allocation concealment in clinical studies to reduce bias.
• Follow STROBE guidelines for observational cohort studies to ensure methodological rigor.
• Perform comprehensive preoperative evaluation including nutritional risk screening and imaging.
• Apply absorbable sutures for stent fixation and intestinal tube construction to facilitate healing and degradation.

References

• National Comprehensive Cancer Network (NCCN) Rectal Cancer Guidelines 2023
• Wu et al. Study on Degradable Stent Application in Rectal Cancer
• STROBE Statement for Observational Studies